Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
On Friday, Mizuho (NYSE:MFG) Securities adjusted its outlook for Teleflex Incorporated (NYSE:TFX), a global provider of medical technologies, by reducing the price target on the company’s shares to $175 from the previous $230. Despite this change, the firm maintained a Neutral rating on the stock. The adjustment comes as TFX shares have declined over 20% in the past week, currently trading near their 52-week low of $135.95. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value metrics.
The revision followed Teleflex’s fourth quarter earnings report, which presented a mix of outcomes. The company’s revenue fell short by $8 million, while it managed to exceed adjusted earnings per share (EPS) expectations by $0.03. Despite the mixed results, InvestingPro data shows the company maintains strong financial health with a current ratio of 2.27 and liquid assets exceeding short-term obligations. The financial results were overshadowed by Teleflex’s announcement that it plans to divide into two independent publicly traded companies. This move is concurrent with Teleflex’s acquisition of the Vascular Intervention business from Biotronik, a private company, for approximately €760 million, or roughly $790 million in cash.
The division will result in the formation of two entities. "RemainCo" will encompass the higher-growth segments, including Vascular Access, Interventional, and Surgical businesses, whereas "NewCo" will include the Urology, Acute Care, and OEM operations. This strategic separation is intended to streamline the operations of both companies. Analysts project that "RemainCo" could emerge with a compelling growth profile, featuring over 6% in top-line growth and high-20s percentage in adjusted operating margins.
The reduction in the price target reflects a cautious outlook due to a weaker guidance and the commencement of the company’s turnaround efforts. Mizuho’s analysts have revised their figures downward in light of these considerations, opting to remain neutral as Teleflex embarks on executing its new strategy.
In other recent news, Teleflex Incorporated reported its fourth-quarter results, revealing adjusted earnings per share of $3.89, which exceeded analyst estimates of $3.86. However, the company’s revenue of $795.4 million fell short of the $813.14 million consensus forecast, and it provided weaker-than-expected guidance for 2025, projecting adjusted earnings per share between $13.95 and $14.35. Teleflex announced plans to split into two publicly traded entities, "RemainCo" and "NewCo," aiming to streamline operations and increase management focus. Additionally, the company plans to acquire Biotronik’s Vascular Intervention business, although financial details were not disclosed.
Analysts have adjusted their outlooks in light of these developments. Raymond (NSE:RYMD) James downgraded Teleflex from Outperform to Market Perform, citing concerns over delayed stabilization in Urolift sales and slower-than-expected progress in key product areas. Piper Sandler also downgraded the stock from Overweight to Neutral and significantly reduced the price target from $255 to $140, reflecting concerns about the company’s future performance and the challenges associated with the planned spinoff. These downgrades reflect a more cautious stance on the stock, given the uncertainties surrounding Teleflex’s strategic shifts and future growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.